| 1 |
Fontana RJ, Liou I, Reuben A, Suzuki A, Fiel MI, Lee W, Navarro V. AASLD practice guidance on drug, herbal, and dietary supplement-induced liver injury. Hepatology 2023;77:1036-65. [PMID: 35899384 DOI: 10.1002/hep.32689] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 2 |
Chen X, Hao Z, Pan H, Liu W, Lu L, Zhang M, He X, Yi H, Tang S. Relationship between common telomere length-related genetic variations, telomere length, and risk of antituberculosis drug-induced hepatotoxicity in Chinese Han population: As assessed for causality using the updated Roussel Uclaf Causality Assessment Method. Fundam Clin Pharmacol 2023. [PMID: 36855016 DOI: 10.1111/fcp.12885] [Reference Citation Analysis]
|
| 3 |
Villa-Jaimes GS, Moshage H, Avelar-González FJ, González-Ponce HA, Buist-Homan M, Guevara-Lara F, Sánchez-Alemán E, Martínez-Hernández SL, Ventura-Juárez J, Muñoz-Ortega MH, Martínez-Saldaña MC. Molecular and Antioxidant Characterization of Opuntia robusta Fruit Extract and Its Protective Effect against Diclofenac-Induced Acute Liver Injury in an In Vivo Rat Model. Antioxidants (Basel) 2023;12. [PMID: 36670975 DOI: 10.3390/antiox12010113] [Reference Citation Analysis]
|
| 4 |
Teschke R. Treatment of Drug-Induced Liver Injury. Biomedicines 2022;11. [PMID: 36672522 DOI: 10.3390/biomedicines11010015] [Reference Citation Analysis]
|
| 5 |
Wang MG, Wu SQ, Zhang MM, He JQ. Urine metabolomics and microbiome analyses reveal the mechanism of anti-tuberculosis drug-induced liver injury, as assessed for causality using the updated RUCAM: A prospective study. Front Immunol 2022;13:1002126. [PMID: 36483548 DOI: 10.3389/fimmu.2022.1002126] [Reference Citation Analysis]
|
| 6 |
Swanson LA, Kassab I, Tsung I, Schneider BJ, Fontana RJ. Liver injury during durvalumab-based immunotherapy is associated with poorer patient survival: A retrospective analysis. Front Oncol 2022;12. [DOI: 10.3389/fonc.2022.984940] [Reference Citation Analysis]
|
| 7 |
Wang M, Wu S, Zhang M, He J. Plasma metabolomic and lipidomic alterations associated with anti-tuberculosis drug-induced liver injury. Front Pharmacol 2022;13. [DOI: 10.3389/fphar.2022.1044808] [Reference Citation Analysis]
|
| 8 |
Naseralallah LM, Aboujabal BA, Geryo NM, Al Boinin A, Al Hattab F, Akbar R, Umer W, Abdul Jabbar L, Danjuma MI. The determination of causality of drug induced liver injury in patients with COVID-19 clinical syndrome. PLoS ONE 2022;17:e0268705. [DOI: 10.1371/journal.pone.0268705] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 9 |
Wang Z, Ma J, He Y, Miu KK, Yao S, Tang C, Ye Y, Lin G. Nrf2-mediated liver protection by 18β-glycyrrhetinic acid against pyrrolizidine alkaloid-induced toxicity through PI3K/Akt/GSK3β pathway. Phytomedicine 2022;102:154162. [PMID: 35598524 DOI: 10.1016/j.phymed.2022.154162] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 10 |
Jagtap U, Basu S, Lokhande L, Bharti N, Sachidanandan C. BML-257, a Small Molecule that Protects against Drug-Induced Liver Injury in Zebrafish. Chem Res Toxicol 2022. [PMID: 35796757 DOI: 10.1021/acs.chemrestox.2c00100] [Reference Citation Analysis]
|
| 11 |
Teschke R, Eickhoff A. Editorial: chronic DILI and HILI - corticosteroid plus glycyrrhizin as standard therapy? Aliment Pharmacol Ther 2022;56:166-7. [PMID: 35689326 DOI: 10.1111/apt.16943] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 12 |
Lewis JH. Digitizing DILI: Who can? RUCAM? RECAM? Hepatology 2022;76:3-5. [PMID: 34990036 DOI: 10.1002/hep.32312] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 13 |
Danan G, Teschke R. Letter to the editor: Electronic RUCAM: Major pitfalls call for caution and proper validation. Hepatology 2022;76:E27. [PMID: 35243675 DOI: 10.1002/hep.32440] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 14 |
Dong H, You J, Zhao Y, Zheng D, Zhong Y, Li G, Weng Z, Luo H, Jiang S. Study on the Characteristics of Small-Molecule Kinase Inhibitors-Related Drug-Induced Liver Injury. Front Pharmacol 2022;13:838397. [DOI: 10.3389/fphar.2022.838397] [Reference Citation Analysis]
|
| 15 |
Wang Z, Ma J, Yao S, He Y, Miu KK, Xia Q, Fu PP, Ye Y, Lin G. Liquorice Extract and 18β-Glycyrrhetinic Acid Protect Against Experimental Pyrrolizidine Alkaloid-Induced Hepatotoxicity in Rats Through Inhibiting Cytochrome P450-Mediated Metabolic Activation. Front Pharmacol 2022;13:850859. [PMID: 35370657 DOI: 10.3389/fphar.2022.850859] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 16 |
Kohn OF, Lew SQ, Wong SS, Sam R, Chen HC, Raiman JG, Leehey DJ, Tzamaloukas AH, Ing TS. Using herbs medically without knowing their composition: are we playing Russian roulette? Curr Med Res Opin 2022;:1-10. [PMID: 35362342 DOI: 10.1080/03007995.2022.2061706] [Reference Citation Analysis]
|
| 17 |
Soares PF, Fernandes MTCF, Souza AS, Lopes CM, Dos Santos DAC, Oliveira DPR, Pereira MG, Prado NMBL, Gomes GSDS, Santos G Junior, Paraná R. Causality imputation between herbal products and HILI: An algorithm evaluation in a systematic review. Ann Hepatol 2021;25:100539. [PMID: 34555512 DOI: 10.1016/j.aohep.2021.100539] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 18 |
Rodríguez A, García-garcía I, Martínez de Soto L, Gómez López De Las Huertas A, Borobia AM, González-torbay A, Akatbach-bousaid I, González-muñoz M, Ramírez E. Utility of Lymphocyte Transformation Test for Assisting Updated Roussel Uclaf Causality Assessment Method in Drug-Induced Liver Injury: A Case-Control Study. Front Pharmacol 2022;13:819589. [DOI: 10.3389/fphar.2022.819589] [Reference Citation Analysis]
|
| 19 |
Herring W, Ciarametaro M, Mauskopf J, Wamble D, Sils B, Dubois R. What might have happened: the impact of interrupting entry of innovative drugs on disease outcomes in the United States. Expert Rev Pharmacoecon Outcomes Res 2022. [PMID: 35098840 DOI: 10.1080/14737167.2022.2035219] [Reference Citation Analysis]
|
| 20 |
Nunes DRDCMA, Monteiro CSDJ, dos Santos JL. Herb-Induced Liver Injury—A Challenging Diagnosis. Healthcare 2022;10:278. [DOI: 10.3390/healthcare10020278] [Reference Citation Analysis]
|
| 21 |
Blanquicett A, Martinez-ávila MC, Mondol Z, Imbeth Acosta P. Toxic Hepatitis Associated With the Use of Contraceptives: A Diagnosis to Bear in Mind. Cureus 2022. [DOI: 10.7759/cureus.21220] [Reference Citation Analysis]
|
| 22 |
Saini K, Bolia R, Bhat NK. Incidence, predictors and outcome of sepsis-associated liver injury in children: a prospective observational study. Eur J Pediatr 2022;181:1699-707. [PMID: 35020050 DOI: 10.1007/s00431-022-04374-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 23 |
Khan Z, Karataş Y, Kıroğlu O. Evaluation of Adverse Drug Reactions in Paediatric Patients: A Retrospective Study in Turkish Hospital. Front Pharmacol 2021;12:786182. [PMID: 34867419 DOI: 10.3389/fphar.2021.786182] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 24 |
Ma J, Li M, Li N, Chan WY, Lin G. Pyrrolizidine Alkaloid-Induced Hepatotoxicity Associated with the Formation of Reactive Metabolite-Derived Pyrrole-Protein Adducts. Toxins (Basel) 2021;13:723. [PMID: 34679016 DOI: 10.3390/toxins13100723] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 25 |
Teschke R, Vongdala N, Quan NV, Quy TN, Xuan TD. Metabolic Toxification of 1,2-Unsaturated Pyrrolizidine Alkaloids Causes Human Hepatic Sinusoidal Obstruction Syndrome: The Update. Int J Mol Sci 2021;22:10419. [PMID: 34638760 DOI: 10.3390/ijms221910419] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 26 |
Woo SM, Davis WD, Aggarwal S, Clinton JW, Kiparizoska S, Lewis JH. Herbal and dietary supplement induced liver injury: Highlights from the recent literature. World J Hepatol 2021;13:1019-41. [PMID: 34630872 DOI: 10.4254/wjh.v13.i9.1019] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
|
| 27 |
Shao Q, Mao X, Zhou Z, Huai C, Li Z. Research Progress of Pharmacogenomics in Drug-Induced Liver Injury. Front Pharmacol 2021;12:735260. [PMID: 34552491 DOI: 10.3389/fphar.2021.735260] [Reference Citation Analysis]
|
| 28 |
Teschke R, Danan G. The LiverTox Paradox-Gaps between Promised Data and Reality Check. Diagnostics (Basel) 2021;11:1754. [PMID: 34679453 DOI: 10.3390/diagnostics11101754] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 29 |
Ho CM, Chen CL, Chang CH, Lee MR, Wang JY, Hu RH, Lee PH. Circulatory Inflammatory Mediators in the Prediction of Anti-Tuberculous Drug-Induced Liver Injury Using RUCAM for Causality Assessment. Biomedicines 2021;9:891. [PMID: 34440095 DOI: 10.3390/biomedicines9080891] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 30 |
Teschke R, Danan G. Idiosyncratic Drug Induced Liver Injury, Cytochrome P450, Metabolic Risk Factors and Lipophilicity: Highlights and Controversies. Int J Mol Sci 2021;22:3441. [PMID: 33810530 DOI: 10.3390/ijms22073441] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
|
| 31 |
Chung Y, Rahim MN, Graham JJ, Zen Y, Heneghan MA. An update on the pharmacological management of autoimmune hepatitis. Expert Opin Pharmacother 2021;22:1475-88. [PMID: 33624559 DOI: 10.1080/14656566.2021.1895747] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 32 |
Teschke R, Danan G. Idiosyncratic Drug-Induced Liver Injury (DILI) and Herb-Induced Liver Injury (HILI): Diagnostic Algorithm Based on the Quantitative Roussel Uclaf Causality Assessment Method (RUCAM). Diagnostics (Basel) 2021;11:458. [PMID: 33800917 DOI: 10.3390/diagnostics11030458] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 7.0] [Reference Citation Analysis]
|
| 33 |
Chen Y, Wang C, Yang H, Huang P, Shi J, Tong Y, Jiang J, Zhang X, Chen W, Xuan Z. Epidemiology of Drug- and Herb-Induced Liver Injury Assessed for Causality Using the Updated RUCAM in Two Hospitals from China. Biomed Res Int 2021;2021:8894498. [PMID: 33954202 DOI: 10.1155/2021/8894498] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 34 |
Stati G, Rossi F, Sancilio S, Basile M, Di Pietro R. Curcuma longa Hepatotoxicity: A Baseless Accusation. Cases Assessed for Causality Using RUCAM Method. Front Pharmacol 2021;12:780330. [PMID: 34776989 DOI: 10.3389/fphar.2021.780330] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 35 |
Lee SH, Kim SY, Yang SB, Jin C, Kwon S, Cho SY, Park SU, Jung WS, Moon SK, Park JM, Ko CN. Safety of co-administration of herbal and conventional medicines on liver and kidney function in stroke patients: A single-center retrospective study. Phytomedicine 2021;81:153435. [PMID: 33338904 DOI: 10.1016/j.phymed.2020.153435] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 36 |
Singh AK, Verma S, Kumar-M P, Soni H, Sharma S, Patil A, Sharma V. Appropriate chemopreventive strategy for anti-tubercular therapy related liver injury is unsettled: Results from a systematic review and network meta-analysis.Expert Rev Clin Pharmacol. 2020;13:1253-1262. [PMID: 33043729 DOI: 10.1080/17512433.2020.1835468] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
|
